Vectron Systems AG

  • WKN: A0KEXC
  • ISIN: DE000A0KEXC7
  • Land: Deutschland

Nachricht vom 09.04.2021 | 12:47

Vectron Systems AG: Preliminary figures 2020

Vectron Systems AG / Key word(s): Preliminary Results
Vectron Systems AG: Preliminary figures 2020

09-Apr-2021 / 12:47 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


In the preparation of the 2020 financial statements, the preliminary figures are now crystallising: in its last forecast for the 2020 business year, Vectron had estimated sales in a range of EUR 25.0 to EUR 29.0 million and EBITDA in a range of EUR -2.0 to EUR 0.25 million. As already reported, Vectron achieved sales of approximately EUR 27.8 million. EBITDA is expected to have been approximately EUR -2.2 million, slightly exceeding the company's estimated range. 

Despite the ongoing obstacles related to the COVID-19 pandemic, the 2021 financial year has started very satisfactorily. Management expects the result to be positive again in Q1 2021.



Contact:
Vectron Systems AG
Tobias Meister
Willy-Brandt-Weg 41
48155 Münster, Germany
phone +49 (0) 2983 908121
mobile +49 (0) 170 2939080
fax +49 (0)251 2856-560
tobias.meister@vectron.de

09-Apr-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Neufassung der Dividendenpolitik der Allianz SE

02. Dezember 2021, 20:33

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021